Explorna Therapeuticssp. z o.o.
Research and experimental development on biotechnology
Overview
Explorna Therapeutics is a company that develops mRNA as a therapeutic platform and offers novel cap analogs for mRNA vaccines and therapeutics. They provide technology and therapeutic programs to pharmaceutical partners, aiming to advance disease treatment and prevention.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-04-22. Active
06 1090 2590 0000 0001 5196 1835- 29 1090 2590 0000 0001 5153 7725
- 92 1090 2590 0000 0001 5153 7852
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
4 public aid cases recorded, with a total value of $5,784,945.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Apr 25, 2025 | Aid for research and development projects: industrial research | $804,226 | Prezes Agencji Badań Medycznych | |
| Apr 21, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $3,846 | Uniwersytet Warszawski | |
| Apr 16, 2020 | Aid for research and development projects: industrial research | $3,909,336 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2020-01-01 | Opracowanie eksperymentalnej immunoterapii przeciwnowotworowej opartej na terapeutycznych mRNA modyfikowanych innowacyjnymi analogami kapu nowej generacji | $4,976,873 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The right to represent the company is vested in two members of the management board acting jointly, or in a member of the management board acting jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Jacek Jemielity (53) | 42 | $567.26 | 23.0769% |
Ms Galleon Gmbh | 87 | $1,175.04 | 47.8022% |
Others | 53 | $715.83 | 29.1209% |
Beneficial owners
| Person | Rights |
|---|---|
Michał Andrzej Sołowow (64)  | Michał sołowow posiada 100% udziałów w kapitale zakładowym ms galleon gmbh z siedzibą w wiedniu, która posiada 47,8% udziałów w kapitale zakładowym explorna therapeutics spółka z ograniczoną odpowiedzialnością |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | |
| Eurxsp. z o.o. | $1,644,555.44 | eurx.com.pl | |
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | |
| Saventic Healthsp. z o.o. | $1,089,246.05 | saventic.com | |
| Syventosp. z o.o. | $970,435.47 | syvento.com | |
| GenxoneS.A. | $665,361.35 | genxone.eu | |
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | |
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | |
| IntelliseqS.A. | $111,419.60 | intelliseq.pl | |
| OPESsp. z o.o. | $100,989.20 | opes.com.pl |
Change history
| Date | Event |
|---|---|
| 2023-11-28 | Share capital change (8,350.00 PLN → 9,100.00 PLN) |
| 2023-03-01 | Address change (Ul. Żwirki I Wigury 101/0.30, 02-089, Warszawa → Ul. Żwirki I Wigury 93/2157, 02-089, Warszawa) |
| 2022-07-20 | Share capital change (7,600.00 PLN → 8,350.00 PLN) |
| 2022-02-07 | Share capital change (6,850.00 PLN → 7,600.00 PLN) |
| 2021-06-10 | Share capital change (6,250.00 PLN → 6,850.00 PLN) |
FAQ
Last updated: 2026-04-13